Long-Term Outcomes of S-1 Combined With Low-Dose Docetaxel as Neoadjuvant Chemotherapy (N-1 Study, Phase II Trial) in Patients With Operable Breast Cancer
CONCLUSION: Our NAC regimen achieved favorable long-term outcomes and significantly improved OS in the pCR group. High TILs, NG 2-3, and some miRNAs may be predictors of pCR.PMID:38462397 | DOI:10.1016/j.clbc.2024.02.014 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 10, 2024 Category: Cancer & Oncology Authors: Soichiro Sasa Hiroaki Inoue Misako Nakagawa Hiroaki Toba Masakazu Goto Kazumasa Okumura Mariko Misaki Tomohiro Inui Sawaka Yukishige Aya Nishisho Naoki Hino Miyuki Kanematsu Yoshimi Bando Hisanori Uehara Akira Tangoku Hiromitsu Takizawa Source Type: research
GSH-activable heterotrimeric nano-prodrug for precise synergistic therapy of TNBC
Biomed Pharmacother. 2024 Mar 8;173:116375. doi: 10.1016/j.biopha.2024.116375. Online ahead of print.ABSTRACTCombination chemotherapy is an effective approach for triple-negative breast cancer (TNBC) therapy, especially when drugs are administered at specific optimal ratios. However, at present, strategies involving precise and controllable ratios based on effective loading and release of drugs are unavailable. Herein, we designed and synthesized a glutathione (GSH)--responsive heterotrimeric prodrug and formulated it with an amphiphilic polymer to obtain nanoparticles (DSSC2 NPs) for precise synergistic chemotherapy of TN...
Source: Cancer Control - March 9, 2024 Category: Cancer & Oncology Authors: Xiaojing Zhang Yansong Chen Jingwei Tang Chen Chen Yanfeng Sun Hao Zhang Mengxiang Qiao Gongsheng Jin Xianfu Liu Source Type: research
GSH-activable heterotrimeric nano-prodrug for precise synergistic therapy of TNBC
Biomed Pharmacother. 2024 Mar 8;173:116375. doi: 10.1016/j.biopha.2024.116375. Online ahead of print.ABSTRACTCombination chemotherapy is an effective approach for triple-negative breast cancer (TNBC) therapy, especially when drugs are administered at specific optimal ratios. However, at present, strategies involving precise and controllable ratios based on effective loading and release of drugs are unavailable. Herein, we designed and synthesized a glutathione (GSH)--responsive heterotrimeric prodrug and formulated it with an amphiphilic polymer to obtain nanoparticles (DSSC2 NPs) for precise synergistic chemotherapy of TN...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 9, 2024 Category: Drugs & Pharmacology Authors: Xiaojing Zhang Yansong Chen Jingwei Tang Chen Chen Yanfeng Sun Hao Zhang Mengxiang Qiao Gongsheng Jin Xianfu Liu Source Type: research
GSH-activable heterotrimeric nano-prodrug for precise synergistic therapy of TNBC
Biomed Pharmacother. 2024 Mar 8;173:116375. doi: 10.1016/j.biopha.2024.116375. Online ahead of print.ABSTRACTCombination chemotherapy is an effective approach for triple-negative breast cancer (TNBC) therapy, especially when drugs are administered at specific optimal ratios. However, at present, strategies involving precise and controllable ratios based on effective loading and release of drugs are unavailable. Herein, we designed and synthesized a glutathione (GSH)--responsive heterotrimeric prodrug and formulated it with an amphiphilic polymer to obtain nanoparticles (DSSC2 NPs) for precise synergistic chemotherapy of TN...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 9, 2024 Category: Drugs & Pharmacology Authors: Xiaojing Zhang Yansong Chen Jingwei Tang Chen Chen Yanfeng Sun Hao Zhang Mengxiang Qiao Gongsheng Jin Xianfu Liu Source Type: research
A Global Phase II Randomized trial comparing Oral Taxane ModraDoc006/r to Intravenous Docetaxel in Metastatic Castration Resistant Prostate Cancer
ModraDoc006, an oral formulation of docetaxel, is co-administered with the cytochrome P450-3A4 and P-glycoprotein inhibitor, ritonavir (r): ModraDoc006/r. The preliminary efficacy and safety of oral ModraDoc006/r was evaluated in a global randomized phase II trial and compared to the current standard chemotherapy regimen of intravenous (i.v.) docetaxel and prednisone. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 9, 2024 Category: Cancer & Oncology Authors: Ulka N. Vaishampayan, Marianne Keessen, Robert Dreicer, Elisabeth I. Heath, Tomas Buchler, P éter F. Árkosy, CsosziTibor Csöszi, Pawel Wiechno, Evgeny Kopyltsov, Sergey V. Orlov, Alexey Plekhanov, Maria Smagina, Sergei Varlamov, Neal D. Shore Tags: Original Research Source Type: research
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab
CONCLUSION: These findings suggest a potential role of Trop-2 expression as a biomarker of resistance to neoadjuvant chemotherapy plus dual HER2 blockade and may become a strategic target for future combinations in HER2-positive EBC patients.PMID:38456970 | DOI:10.1007/s10549-024-07292-z (Source: Cell Research)
Source: Cell Research - March 8, 2024 Category: Cytology Authors: Mar ía Gion Juan Jos é García-Mosquera Jos é Manuel Pérez-García Vicente Peg Manuel Ruiz-Borrego Agostina Stradella Bego ña Bermejo Jos é Antonio Guerrero Laura L ópez-Montero Mario Mancino Jos é Rodríguez-Morató Gabriele Antonarelli Miguel Sa Source Type: research
Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A phase II single-arm study
CONCLUSIONS: This dual HER2-blockade with sequential polychemotherapy showed promising activity with rapid tumor regression in HER2-positive BC. Importantly, this regimen showed an acceptable safety profile, especially a low risk of cardiac events, suggesting it as an attractive treatment approach with a favorable risk-benefit balance.PMID:38455369 | PMC:PMC10915636 | DOI:10.21147/j.issn.1000-9604.2024.01.06 (Source: Cancer Control)
Source: Cancer Control - March 8, 2024 Category: Cancer & Oncology Authors: Yaping Yang Liang Jin Yudong Li Nanyan Rao Chang Gong Shunrong Li Jiannan Wu Jinghua Zhao Linxiaoxiao Ding Fengxia Gan Jun Zhang Ruifa Feng Zhenzhen Liu Qiang Liu Source Type: research
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab
CONCLUSION: These findings suggest a potential role of Trop-2 expression as a biomarker of resistance to neoadjuvant chemotherapy plus dual HER2 blockade and may become a strategic target for future combinations in HER2-positive EBC patients.PMID:38456970 | DOI:10.1007/s10549-024-07292-z (Source: Cell Research)
Source: Cell Research - March 8, 2024 Category: Cytology Authors: Mar ía Gion Juan Jos é García-Mosquera Jos é Manuel Pérez-García Vicente Peg Manuel Ruiz-Borrego Agostina Stradella Bego ña Bermejo Jos é Antonio Guerrero Laura L ópez-Montero Mario Mancino Jos é Rodríguez-Morató Gabriele Antonarelli Miguel Sa Source Type: research
Audit of Hypersensitivity Reactions (HSRs) of Patients with Breast Cancer being Treated with Nab-paclitaxel after Severe HSR to Prior Taxane Chemotherapy; is it Safe?
Purpose: Taxanes (docetaxel and paclitaxel) are standard systemic therapies in treating breast and other cancers. Hypersensitivity reactions (HSRs) are reported in about 10% of patients treated with paclitaxel, with severe reactions in 2 –5%, even with pre-medication [1]. There is also up to 90% cross-reactivity between paclitaxel and docetaxel, for patients who experience a HSR [2]. Nanoparticle albumin-bound (nab-)paclitaxel was initially developed with the aim of reducing toxicity [3]. Early clinical trials of nab-paclitaxel re ported lower rates of HSRs [4], but no published data could be found, other than case repor...
Source: Clinical Oncology - March 8, 2024 Category: Radiology Authors: M. Jaschke, X. Ren, C. Michie Source Type: research
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab
ConclusionThese findings suggest a potential role of Trop-2 expression as a biomarker of resistance to neoadjuvant chemotherapy plus dual HER2 blockade and may become a strategic target for future combinations in HER2-positive EBC patients. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 8, 2024 Category: Cancer & Oncology Source Type: research
Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial
ConclusionsPerioperative DOS improved MPR significantly and tended to produce longer PFS compared to SOX in LAG/GEJ cancer in Asia, and might be considered as a preferred option for perioperative chemotherapy and worth further investigation. (Source: Gastric Cancer)
Source: Gastric Cancer - March 8, 2024 Category: Gastroenterology Source Type: research
Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment
ConclusionThese results suggest that delayed loperamide administration can be added to ritonavir-boosted oral docetaxel treatment, without affecting the overall systemic exposure of docetaxel. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - March 8, 2024 Category: Cancer & Oncology Source Type: research
BRCA2 ‐positive lung adenocarcinoma treated with olaparib: A case report
A 66-year-old woman diagnosed with stage IVA lung adenocarcinoma underwent multiple lines of treatment, including chemotherapy and targeted therapies. After discovering a BRCA2 gene mutation through genomic profiling, she initiated olaparib treatment, resulting in approximately 2 years of stable disease. AbstractA 66-year-old woman was found to have abnormal shadows on a chest radiograph at a previous hospital 4 years ago, which led to a diagnosis of lung adenocarcinoma, cT2aN1M1b stage IVA. First-line treatment included carboplatin and paclitaxel plus thoracic radiotherapy and stereotactic radiation therapy for brai...
Source: Respirology Case Reports - March 7, 2024 Category: Respiratory Medicine Authors: Takumi Motohashi,
Kazutoshi Isobe,
Takahiro Yoshizawa,
Yusuke Usui,
Hiroshige Shimizu,
Muneyuki Sekiya,
Shion Miyoshi,
Yasuhiko Nakamura,
Naohisa Urabe,
Susumu Sakamoto,
Sakae Homma,
Sota Sadamoto,
Naobumi Tochigi,
Kazuma Kishi Tags: CASE REPORT Source Type: research
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial
ConclusionOur results showed high pCR rates with Trastuzumab and Pertuzumab associated to chemotherapy. They were similar in TOP2A + and TOP2A- groups and the current role of neoadjuvant anthracycline-based chemotherapy remains questioned.Trial registration numberNCT02339532 (registered on 14/12/14). (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 7, 2024 Category: Cancer & Oncology Source Type: research
Quantitative analysis of the effect of docetaxel-induced edema on quality of life in patients with breast cancer and related factors: a prospective cohort study
Systemic edema is an adverse effect of docetaxel chemotherapy and causes distress to patients, including those receiving this agent for breast cancer. However, its characteristics and factors related to its ef... (Source: BMC Women's Health)
Source: BMC Women's Health - March 7, 2024 Category: OBGYN Authors: Tomoko Izawa, Ami Kobayashi, Masahiro Kawashima, Nobuko Kawaguchi-Sakita, Akiyoshi Nakakura, Yuki Kataoka, Kenichiro Shide, Yukiko Mori, Kazuhiro Yamazaki, Masakazu Toi and Harue Arao Tags: Research Source Type: research
